BioInvent International: BioInvent Reveals Solid Data with its TNFR2 Antibody BI-1808 and KEYTRUDA in Advanced Ovarian Cancer at ASCO

BioInvent International (STO:BINV)24% confirmed ORR (including complete response) in heavily pretreated patients (n=25) with advanced ovarian cancer who received BI-1808 and KEYTRUDA - multiplying by ...

Moderna, Merck cancer combo cuts melanoma spread risk at five years

Moderna and Merck's combination therapy for skin cancer helped reduce risk of cancer spreading to another part of the body ...
PharmiWeb

BioInvent Reveals Solid Data with its TNFR2 Antibody BI-1808 and KEYTRUDA(R) (pembrolizumab) in Advanced Ovarian Cancer at ASCO

BioInvent International (STO:BINV)24% confirmed ORR (including complete response) in heavily pretreated patients (n=25) with advanced ovarian cancer who received BI-1808 and KEYTRUDA - multiplying by ...
The Manila Times

Silexion Therapeutics Reports Positive Preliminary Immunotherapy Findings for SIL204 in KRAS-Driven Pancreatic Cancer

Preliminary results from a preclinical study demonstrated statistically significant increase in MHC-I expression following ...

Could this be the moment that drug manufacturing takes off in orbit?

NASA has enabled scientists to study the impact of microgravity on drug development for decades, beginning with the Space Shuttle. This work accelerated in the 2010s, with the completion of the ...
The Logical Indian

Eli Lilly Tried To Start An Obesity Conversation, Regulators Heard A Sales Pitch

India’s regulators are tightening oversight as obesity drug makers race to shape demand in the country’s emerging weight-loss ...

Eli Lilly halts India obesity awareness campaign after regulatory scrutiny

In a 16-page letter dated April 10 and sent to the Drugs Controller General of India, Lilly said it had halted the campaign 'out of an abundance of regulatory caution' following a March advisory ...
Hosted on MSN

Biotech M&A on track for $250B amid looming patent cliff

Biopharma mergers and acquisitions have surged in early 2026, with $84 billion in deals announced in Q1, the strongest start since 2019. Large drugmakers are racing to acquire assets ahead of major ...

Big Pharma M&A set for mega year as patent expiries drive deal urgency

Biotech dealmaking is on pace for a bumper year in 2026, with large drugmakers on an acquisition spree to boost their pipelines ahead of upcoming patent losses.
Wall Street Journal

Merck First-Quarter Sales Rise on Continued Keytruda Growth

Merck reported higher first-quarter sales and raised its full-year earnings guidance as demand for its flagship Keytruda cancer drug continues to grow. Sales rose 5% to $16.29 billion, boosted by 12% ...

Bernstein flags jobs, AI, and subsidy risks in open letter to PM Modi

Bernstein flags risks on jobs, AI readiness, subsidies, and manufacturing in India in an open letter to Narendra Modi, ...
Yahoo Finance

FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...